S&P 500 7,650.50 +0.17%
Nasdaq 26,522.55 +0.39%
S&P/TSX 35,806.65 −0.19%
Apple 336.13 −0.26%
Nvidia 222.27 +1.34%
Microsoft 493.78 −0.80%
Shopify 179.34 −0.37%
Royal Bank 284.45 −0.17%
CAD/USD 0.7149 +0.02%
CLOSED · 05:05 ET
Market ClerkRecap
Sun Sep 20 · markets closed2 signals on Sep 19263 insider buys this week · $115.4MCIRO short report next: Sep 30The week ahead
CE
INSIDER · DNTH · Dianthus Therapeutics, Inc. /DE/ · CHIEF ACCOUNTING OFFICER

CARR EDWARD

Every open-market transaction filed under this name, Sep 17 to Sep 17.

Filings
5
0 buys · 5 sells
Bought
open market, at cost
Sold
$2M
includes scheduled sales
Buys since
no current price on file

Filings

SEC FORM 4 · OPEN MARKET
TradedTickerCompanyRoleTypeSharesPriceValueSince
Sep 17DNTHDianthus Therapeutics, Inc. /DE/CHIEF ACCOUNTING OFFICERSell700$104.39$73K
Sep 17DNTHDianthus Therapeutics, Inc. /DE/CHIEF ACCOUNTING OFFICERSell1,100$103.20$114K
Sep 17DNTHDianthus Therapeutics, Inc. /DE/CHIEF ACCOUNTING OFFICERSell3,501$102.39$358K
Sep 17DNTHDianthus Therapeutics, Inc. /DE/CHIEF ACCOUNTING OFFICERSell6,771$101.37$686K
Sep 17DNTHDianthus Therapeutics, Inc. /DE/CHIEF ACCOUNTING OFFICERSell7,928$100.43$796K

"Since" is the stock's move from the filed price to the latest quote on file, not a scored call. Open-market purchases and sales only; option exercises and grants are excluded.